HK Stock Market Move | MEDBOT-B(02252) surged by over 5%, and the total number of installations for TiMai global commercialization has exceeded 200. The company's commercialization efforts continue to accelerate.

MEDBOT-B (02252) rose by over 5%, as of the time of release, it increased by 4.95% to HKD 22.88, with a turnover of HKD 26.0759 million. In terms of news, MicroPort Siasun Robot & Automation announced that after the global commercialization orders of the group's core product, the Thoracic Surgical Robot Siasun Robot & Automation, exceeded 300 units, Thoracic has recently landed at the top medical institution HM Hospitals in Spain and completed the 200th global commercial installation, all of which have obtained acceptance reports from end customers. According to public statistics, as of the current year, Thoracic's global addition of commercial installations ranks first domestically and second globally. The company stated that the breakthrough of the dual milestone of commercial orders and installation volume marks the acceleration of Thoracic's global clinical ecology, real-world application system, and remote collaboration network.